UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

June 07, 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

June 06, 2018

John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles (UCLA) School of Medicine, discusses immunogenicity in ovarian cancer.

June 06, 2018

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses improving methods of early detection of ovarian cancer.

June 04, 2018

Nisha Bansal, MD, gynecologic oncologist, University of California, Los Angeles, discusses frontline chemotherapeutic approaches for patients with ovarian cancer.

June 01, 2018

Christopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses palliative care for patients with ovarian cancer.

May 31, 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses drug development for the treatment of patients with soft tissue sarcomas.

May 30, 2018

Deborah Krakow, MD, professor and chair, Department of Obstetrics and Gynecology, professor of Orthopaedic Surgery and Human Genetics, University of California, Los Angeles, discusses genetic testing in patients with ovarian cancer.

May 30, 2018

Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses combination clinical trials of PARP inhibitors in patients with ovarian cancer.

May 29, 2018

Sanaz Memarzadeh, MD, PhD, gynecologic oncologist, professor of obstetrics and gynecology, University of California, Los Angeles, discusses p53 reactivation in the treatment of patients with ovarian cancer.

May 29, 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.

May 25, 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.

May 25, 2018

Joshua G. Cohen, MD, assistant professor, Division of Gynecologic Oncology, University of California, Los Angeles, discusses the evolution of surgery in the treatment of patients with ovarian cancer.

May 07, 2018

Maggie DiNome, MD, discusses the evolution of surgical approaches in patients with early-stage breast cancer.

May 05, 2018

Kelly McCann, MD, PhD, discusses the therapies available for patients with HER2-positive breast cancer and the potential benefit with additional subtyping in the field.

May 02, 2018

Susan A. McCloskey, MD, discusses the use of postoperative radiation in patients with breast cancer.

May 01, 2018

Sara Hurvitz, MD, shares insight on the 3 CDK4/6 inhibitors approved in HR-positive breast cancer, and looks toward the future of these agents, which will likely include combination strategies.

April 30, 2018

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses when to use a biosimilar over the originator drug.

April 27, 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses the clinical use of biosimilars in oncology.

April 27, 2018

Susan A. McCloskey, MD, MSHS, assistant professor of radiation oncology, University of California Los Angeles (UCLA) Medical Center, Jonsson Comprehensive Cancer Center, discusses the evolution of postoperative radiation in patients with breast cancer.

April 25, 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of biosimilars in clinical practice.